Ovid Therapeutics Inc. OVID
Biotechnology: Pharmaceutical Preparations · IPO 2017 · data as of November 13, 2026
Ovid Therapeutics Inc. (OVID) is a healthcare company listed in the US with a market value of about $479M. In the twelve months to September 30, 2026 it had revenue of $1M and net income of -$43M, a net margin of -2971.3%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -10% a year, a 5-year average ROIC of -26%.
About Ovid Therapeutics
Ovid Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2017. Revenue went from $13M in 2020 to $7M in 2025, a decline of about 10.5% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 168% over three years (dilution for shareholders). It spends 353% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $7M | $566000 | $392000 | $2M | $208M | $13M | — | — | — | — |
| Net income | -$43M | -$17M | -$26M | -$52M | -$54M | $123M | -$81M | -$60M | -$52M | -$65M | -$22M |
| Free cash flow | -$58M | -$38M | -$56M | -$46M | -$56M | $118M | -$52M | -$51M | -$46M | -$32M | -$18M |
| EPS (diluted) | $-0.28 | $-0.09 | — | $-0.74 | $-0.77 | $1.76 | $-1.39 | — | $-2.11 | $-3.35 | $-2.28 |
| Net margin | -2971.3% | -240.1% | -4670.1% | -13351.8% | -3604.7% | 59.0% | -642.3% | — | — | — | — |
| ROIC | — | -29.5% | -74.6% | -57.1% | -37.3% | 68.4% | -186.6% | -69.3% | -107.8% | -61.6% | -36.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $6.15, 142% above the current price; targets range from $4.00 to $9.00; the consensus rating is “Strong buy”; expected EPS is $-0.40 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Ovid Therapeutics pay a dividend?
Not currently.
Is Ovid Therapeutics a good stock to buy?
We do not give buy or sell advice. Ovid Therapeutics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.